MCID: DBT006
MIFTS: 50

Diabetic Macular Edema

Categories: Cardiovascular diseases, Eye diseases

Aliases & Classifications for Diabetic Macular Edema

MalaCards integrated aliases for Diabetic Macular Edema:

Name: Diabetic Macular Edema 12 55 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:9191
ICD9CM 35 362.07
UMLS 73 C0730285

Summaries for Diabetic Macular Edema

MalaCards based summary : Diabetic Macular Edema is related to macular retinal edema and retinal vein occlusion. An important gene associated with Diabetic Macular Edema is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Ranibizumab and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and retina, and related phenotypes are cardiovascular system and hematopoietic system

Related Diseases for Diabetic Macular Edema

Diseases related to Diabetic Macular Edema via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 110)
# Related Disease Score Top Affiliating Genes
1 macular retinal edema 32.2 CCL2 ICAM1 IL6 VEGFA
2 retinal vein occlusion 30.6 CCL2 IL6 SERPINF1 VEGFA
3 macular degeneration, age-related, 1 30.5 CCL2 FGF2 SERPINF1 VEGFA
4 ischemia 30.5 ICAM1 NOS3 VEGFA
5 macular dystrophy, dominant cystoid 30.3 PRKCB SERPINF1 VEGFA
6 macular holes 30.2 CCL2 SERPINF1 VEGFA
7 retinal vascular disease 30.2 CCL2 ICAM1 SERPINF1 VEGFA
8 microvascular complications of diabetes 5 30.1 FGF2 ICAM1 NOS3 PRKCB SERPINF1 TEK
9 central retinal vein occlusion 30.0 IL6 SERPINF1 VEGFA
10 sleep apnea 30.0 ICAM1 IL6 NOS3
11 microvascular complications of diabetes 1 29.7 CCL2 FGF2 ICAM1 SERPINF1 SST VEGFA
12 cataract 10.5
13 retinal detachment 10.4
14 diabetes mellitus 10.4
15 microvascular complications of diabetes 2 10.3
16 vitreous detachment 10.3
17 degos 'en cocarde' erythrokeratoderma 10.2
18 spinal disease 10.2 IL6 VEGFA
19 blood group, globoside system 10.2 IL6 VEGFA
20 poems syndrome 10.2 IL6 VEGFA
21 diabetic cataract 10.2 SERPINF1 VEGFA
22 primary effusion lymphoma 10.2 IL6 VEGFA
23 diabetic foot ulcers 10.2 CCL2 IL6
24 pyogenic granuloma 10.2 TEK VEGFA
25 herpes simplex virus keratitis 10.2 CCL2 ICAM1
26 denture stomatitis 10.2 CCL2 IL6
27 endophthalmitis 10.2 ICAM1 VEGFA
28 hydrocele 10.2 ICAM1 VEGFA
29 capillary hemangioma 10.2 TEK VEGFA
30 acute proliferative glomerulonephritis 10.2 CCL2 ICAM1
31 retinal vascular occlusion 10.2 CCL2 VEGFA
32 stachybotrys chartarum 10.2 CCL2 IL6
33 chronic eosinophilic pneumonia 10.1 CCL2 ICAM1
34 eales disease 10.1 IL6 SERPINF1 VEGFA
35 kuhnt-junius degeneration 10.1
36 leukostasis 10.1 ICAM1 VEGFA
37 hemifacial spasm 10.1 NOS3 VEGFA
38 cortical thymoma 10.1 ICAM1 SST
39 patellar tendinitis 10.1 NOS3 VEGFA
40 viral meningitis 10.1 CCL2 IL6
41 critical limb ischemia 10.1 IL6 TEK VEGFA
42 erdheim-chester disease 10.1 CCL2 SST
43 hypersensitivity reaction type iii disease 10.1 ICAM1 IL6
44 urinary system disease 10.1 CCL2 IL6 VEGFA
45 idiopathic interstitial pneumonia 10.1 CCL2 ICAM1 VEGFA
46 endometriosis 10.1 CCL2 IL6 VEGFA
47 carcinoid syndrome 10.1 SST VEGFA
48 post-thrombotic syndrome 10.1 CCL2 ICAM1 IL6
49 nervous system disease 10.1 CCL2 IL6 VEGFA
50 extrinsic cardiomyopathy 10.1 CCL2 ICAM1 IL6

Graphical network of the top 20 diseases related to Diabetic Macular Edema:



Diseases related to Diabetic Macular Edema

Symptoms & Phenotypes for Diabetic Macular Edema

MGI Mouse Phenotypes related to Diabetic Macular Edema:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.03 FGF2 ICAM1 IL6 NOS3 PRKCB SERPINF1
2 hematopoietic system MP:0005397 10.02 FGF2 ICAM1 IL6 NOS3 PRKCB SERPINF1
3 homeostasis/metabolism MP:0005376 9.97 CASP14 FGF2 ICAM1 IL6 NOS3 PRKCB
4 immune system MP:0005387 9.91 CCL2 ICAM1 IL6 NOS3 PRKCB SERPINF1
5 digestive/alimentary MP:0005381 9.88 ICAM1 IL6 NOS3 SERPINF1 SST VEGFA
6 muscle MP:0005369 9.63 FGF2 ICAM1 IL6 NOS3 TEK VEGFA
7 nervous system MP:0003631 9.61 FGF2 ICAM1 IL6 NOS3 PRKCB SERPINF1
8 vision/eye MP:0005391 9.17 FGF2 ICAM1 IL6 NOS3 SERPINF1 TEK

Drugs & Therapeutics for Diabetic Macular Edema

Drugs for Diabetic Macular Edema (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 237)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranibizumab Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 347396-82-1 459903
2
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 216974-75-3
3
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-02-2 5743
4
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1177-87-3
5
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
6
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
7
Linagliptin Approved Phase 4 668270-12-0 10096344
8
Povidone-iodine Approved Phase 4,Phase 3,Not Applicable 25655-41-8
9
Triamcinolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 124-94-7 31307
10
Diclofenac Approved, Vet_approved Phase 4,Phase 1 15307-86-5 3033
11
Lidocaine Approved, Vet_approved Phase 4,Not Applicable 137-58-6 3676
12
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 67-73-2 6215
13
Nepafenac Approved, Investigational Phase 4,Phase 3,Phase 2 78281-72-8 151075
14
Betamethasone Approved, Vet_approved Phase 4,Phase 2,Phase 3 378-44-9 9782
15
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
16 Homatropine Approved Phase 4 87-00-3
17 tannic acid Approved Phase 4,Phase 3,Phase 1,Phase 2
18
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 94-09-7, 1994-09-7 2337
19
Verteporfin Approved, Investigational Phase 4 129497-78-5
20
Glimepiride Approved Phase 4 93479-97-1 3476
21
Empagliflozin Approved Phase 4 864070-44-0
22
2,4-thiazolidinedione Investigational Phase 4 2295-31-0
23
Bromfenac Approved July 1997 Phase 4,Phase 1 91714-94-2 60726
24
Lactitol Investigational Phase 4 585-86-4 3871
25 Immunologic Factors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
26 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
27 Mitogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
29 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
30 Endothelial Growth Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
32
protease inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
33 Hormone Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
34 Hormones Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
35 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
36 glucocorticoids Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
37 Autonomic Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
38 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
39 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
40 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
41 BB 1101 Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
42 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
43 Antiemetics Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
44 Immunoglobulins Phase 4,Phase 2,Phase 3,Phase 1
45 Antibodies Phase 4,Phase 2,Phase 3,Phase 1
46 Hypoglycemic Agents Phase 4,Not Applicable
47 Cardiac Glycosides Phase 4
48 Glycoside Hydrolase Inhibitors Phase 4
49 Incretins Phase 4
50 Dipeptidyl-Peptidase IV Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 455)
# Name Status NCT ID Phase Drugs
1 Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Patients With Persistent Diabetic Macular Edema Following Treatment With Ranibizumab: An Interventional Prospective Study Unknown status NCT02651168 Phase 4
2 The Endurance 1 Trial Unknown status NCT02297204 Phase 4 aflibercept 2.0 mg
3 Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema Unknown status NCT02096874 Phase 4 Bevacizumab
4 POSTERIOR SUB-TENON'S Avastin Unknown status NCT00567372 Phase 4 bevacizumab (Sub-tenon´s injection)
5 Effect of Dexamethasone Implant in Hard Exudate Complicated With Diabetic Macular Edema Unknown status NCT02399657 Phase 4 Intravitreal dexamethasone 0.7mg implant
6 To Compare Anti-VEGF Monotherapy With Anti-VEGF and EPM Grid Laser Combination Therapy for Diabetic Macular Edema Unknown status NCT02462304 Phase 4 ranibizumab;Bevacizumab
7 Laser Therapy Combined With Intravitreal Aflibercept vs Intravitreal Aflibercept Monotherapy (LADAMO) Unknown status NCT02432547 Phase 4 Aflibercept
8 Comparison of the Effects of Bevacizumab Before vs After Pattern Panretinal Photocoagulation Unknown status NCT00804206 Phase 4 bevacizumab;bevacizumab
9 Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion Unknown status NCT01827722 Phase 4 Ozurdex;Ranibizumab;Combination Ozurdex with Ranibizumab PRN
10 Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
11 Panretinal Photocoagulation for Proliferative Diabetic Retinopathy in a Single Session Using Low Fluence Parameters Unknown status NCT01023698 Phase 4
12 A One-year Randomized Controlled Trial Evaluating the Impact of Pioglitazone Versus Linagliptin on Bone Turnover Markers Unknown status NCT02429232 Phase 4 Pioglitazone;Linagliptin
13 Intravitreal Macugen for Ischaemic Diabetic Macular Oedema Completed NCT01175070 Phase 4 Intravitreal injection of pegaptanib sodium
14 Intraocular Anti-VEGF Compared With Intraocular Triamcinolone in Patients With Diabetic Macular Edema Completed NCT00682539 Phase 4 Bevacizumab (Avastin);Triamcinolone;Sham
15 Multicenter Study to Evaluate the Efficacy of Treat and Extend Regimen of Aflibercept (EYLEA) as a Second Line Treatment for Diabetic Macular Edema Completed NCT02633852 Phase 4 Aflibercept
16 A Pilot Study on the Effect and Safety of Iluvien® in Chronic Diabetic Macular Edema Patients Completed NCT02359526 Phase 4 IlUVIEN
17 Efficacy of Ranibizumab Therapy With Aflibercept in Patients With Diabetic Macular Edema Completed NCT02646670 Phase 4 Ranibizumab;Aflibercept;Ranibizumab and Aflibercept;Aflibercept and ranibizumab
18 Topical Nepafenac as Supplement for Diabetic Macular Edema Completed NCT02443012 Phase 4 Topical Gutt Nepafenac 0.1%
19 Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Alone Versus Ozurdex Given Every 3 Months for Treatment of Persistent Diabetic Macular Edema Completed NCT02036424 Phase 4 Ozurdex;Bevacizumab
20 Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Macular Edema in Subjects Who Completed the Three Year VISTA-DME Trial (The Endurance 2 Trial) Completed NCT02368756 Phase 4 Aflibercept
21 Efficacy Study of Triamcinolone and Bevacizumab Intravitreal for Treatment of Diabetic Macular Edema Completed NCT00737971 Phase 4 Bevacizumab intravitreal;Triamcinolone;Triamcinolone + Bevacizumab
22 Ozurdex as Adjunct to Avastin Compared to Avastin Alone in Treatment of Patients With Diabetic Macular Edema Completed NCT01309451 Phase 4 Bevacizumab;dexamethasone intravitreal implant
23 Randomized, Double Blind Trial of Bromfenac BID (0.09%) as an Adjunct to Argon Laser Therapy in the Treatment of Diabetic Macular Edema. Completed NCT00758628 Phase 4 Bromefenac;Blink
24 Early Anatomical, Physiological, and Clinical Changes in Diabetic Macular Edema After Intravitreal Aflibercept Injection Completed NCT03453281 Phase 4 Aflibercept Injection [Eylea]
25 Unilateral Bevacizumab for Bilateral Diabetic Macular Edema Completed NCT00496405 Phase 4 bevacizumab
26 Ozurdex for Diabetic Macular Edema Treated With Pars Plana vitrEctomy and Membrane RemovAl (OPERA Study) Completed NCT01613716 Phase 4 Ozurdex
27 Intraoperative Dexamethasone Implant Improves Outcome of Cataract Surgery With Diabetic Macular Edema Completed NCT01546402 Phase 4 Dexamethasone Drug delivery system (Ozurdex)
28 Ranibizumab "Treat and Extend" in Diabetic Macular Edma Completed NCT01297569 Phase 4 Ranibizumab
29 Performance Assessment Tests in Working Individuals With DME Following Treatment With Ranibizumab Completed NCT02107131 Phase 4 Intravitreal ranibizumab 0.3mg
30 Treatment of Diabetic Macular Edema (DME) With Anti-VEGF and Focal Laser Completed NCT03590444 Phase 4 Ranibizumab 0.5 MG/0.05 ML Intraocular Solution
31 Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment Completed NCT01257815 Phase 4 Ranibizumab
32 Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema. Completed NCT02140411 Phase 4 Ranibizumab Intravitreal injections
33 Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study Completed NCT01486238 Phase 4 Macugen® pegaptanib sodium
34 Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME Trial Completed NCT02299336 Phase 4 Aflibercept
35 Peripheral and Macular Retinal Vascular Perfusion and Leakage in DME and RVO Completed NCT02503540 Phase 4 Aflibercept
36 Variable Interval Versus Set Interval Aflibercept for DME Completed NCT02392364 Phase 4 Intravitreal Aflibercept Injection
37 A Non-Randomized, Open-Label, Single Center Phase 4 Study of the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (Laser, Anti-VEGF) With or Without Intravitreal Corticosteroid Therapy Completed NCT02472366 Phase 4 ILUVIEN
38 Investigation of the Change of Vision-related Quality of Life in Subjects Treated With Aflibercept According to EU Label for DME. Completed NCT02581995 Phase 4 Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)
39 Evaluation of the Effect of Intravitreal Injections of Anti-VEGF on Macular Perfusion in Diabetic Patients Using OCTA Completed NCT03246152 Phase 4 Bevacizumab
40 Lucentis (Ranibizumab) in Diabetic Macular Oedema: a Treatment Evaluation Completed NCT01223612 Phase 4 Ranibizumab
41 Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema Completed NCT02366468 Phase 4 ranibizumab 0.5 mg
42 Morphological and Functional Retinal Changes Following Retinal Photocoagulation Completed NCT00682240 Phase 4
43 Intravitreal Diclofenac Versus Intravitreal Ranibizumab for the Treatment of Diabetic Macular Edema. Recruiting NCT03458923 Phase 4 Diclofenac Sodium 0.1 ml containing 500µg;Ranibizumab 0.5 mg Solution for Injection
44 Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Diabetic Macular Edema Recruiting NCT02441907 Phase 4 aflibercept
45 Effect of Aflibercept (Eylea®) in the Management of Bevacizumab (Avastin®) Resistant Diabetic Macular Edema Recruiting NCT02924987 Phase 4 Aflibercept Injection
46 Influence of Diabetes Control on Treatment of Diabetic Macular Edema With Ranibizumab Recruiting NCT02665689 Phase 4 ranibizumab
47 Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis Recruiting NCT03097068 Phase 4 Lucentis
48 Treat-and-extend Regimen of Aflibercept in Diabetic Macular Edema (VIBIM Study) Recruiting NCT02788877 Phase 4 aflibercept
49 Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab Recruiting NCT02559180 Phase 4 aflibercept
50 IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab Recruiting NCT03340610 Phase 4 Alflibercept

Search NIH Clinical Center for Diabetic Macular Edema

Genetic Tests for Diabetic Macular Edema

Anatomical Context for Diabetic Macular Edema

MalaCards organs/tissues related to Diabetic Macular Edema:

41
Eye, Endothelial, Retina, Testes, Bone, Kidney, Heart

Publications for Diabetic Macular Edema

Articles related to Diabetic Macular Edema:

(show top 50) (show all 1348)
# Title Authors Year
1
Comparison of the Efficacy of Sub-Tenon versus Intravitreal Triamcinolone Acetonide Injection during Cataract Surgery for Diabetic Macular Edema. ( 30041252 )
2019
2
Effectiveness and Safety of Intravitreal Dexamethasone Implant (Ozurdex) in Patients with Diabetic Macular Edema: A Real-World Experience. ( 30408801 )
2019
3
Short-term outcomes after the loading phase of intravitreal bevacizumab and subthreshold macular laser in non-center involved diabetic macular edema. ( 29977811 )
2018
4
Comparison of Intravitreal Aflibercept and Ranibizumab following Initial Treatment with Ranibizumab in Persistent Diabetic Macular Edema. ( 29850202 )
2018
5
Aflibercept for clinically significant diabetic macular edema: 12-month results in daily clinical practice. ( 29386883 )
2018
6
Efficiency of fenofibrate in facilitating the reduction of central macular thickness in diabetic macular edema. ( 29283132 )
2018
7
Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema: Does Flavor Matter? ( 29392302 )
2018
8
Diabetic macular edema treated with ranibizumab following bevacizumab failure in Israel (DERBI study). ( 29916263 )
2018
9
Treatment Efficacy and Compliance in Patients with Diabetic Macular Edema Treated with Ranibizumab in a Real-Life Setting. ( 29850205 )
2018
10
Visual Outcomes Based on Early Response to Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema. ( 29316563 )
2018
11
One-Year Outcome of Conbercept Therapy for Diabetic Macular Edema. ( 29265939 )
2018
12
Intravitreal dexamethasone implants for diabetic macular edema. ( 29375995 )
2018
13
Management of diabetic macular edema with intravitreal dexamethasone implants: Expert recommendations using a Delphi-based approach. ( 29882421 )
2018
14
Multimodal Imaging in Diabetic Macular Edema. ( 29376234 )
2018
15
Real-life experience of ranibizumab for diabetic macular edema in Taiwan. ( 29926364 )
2018
16
Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial. ( 29336896 )
2018
17
Choroidal Thickness in Diabetic Macular Edema Compared to Normal Controls. ( 29944846 )
2018
18
Early Retinal and Choroidal Coat Thickness Changes After Intravitreal Dexamethasone Implant Injection for Diabetic Macular Edema. ( 29866639 )
2018
19
Basis and Design of a Randomized Clinical Trial to Evaluate the Effect of Levosulpiride on Retinal Alterations in Patients With Diabetic Retinopathy and Diabetic Macular Edema. ( 29896154 )
2018
20
Detailed analysis of retinal morphology in patients with diabetic macular edema (DME) randomized to ranibizumab or triamcinolone treatment - reply to the letter to the editor. ( 29368041 )
2018
21
Pharmacology of Corticosteroids for Diabetic Macular Edema. ( 29297055 )
2018
22
Evaluation of the effect of combined intravitreal ranibizumab injection and sub-tenon steroid injection in the treatment of resistant diabetic macular edema. ( 29943100 )
2018
23
Apelin-13 Is an Early Promoter of Cytoskeleton and Tight Junction in Diabetic Macular Edema via PI-3K/Akt and MAPK/Erk Signaling Pathways. ( 29850504 )
2018
24
Prevalence of diabetic retinopathy and diabetic macular edema in a primary care-based teleophthalmology program for American Indians and Alaskan Natives. ( 29924846 )
2018
25
Evaluation of Navigated Laser Photocoagulation (Navilas 577+) for the Treatment of Refractory Diabetic Macular Edema. ( 29854426 )
2018
26
ILUVIEN<sup>Ar</sup> technology in the treatment of center-involving diabetic macular edema: a review of the literature. ( 29943691 )
2018
27
Quantitative assessment of macular contraction and vitreoretinal interface alterations in diabetic macular edema treated with intravitreal anti-VEGF injections. ( 29922890 )
2018
28
Oral administration of a curcumin-phospholipid formulation (MerivaAr) for treatment of chronic diabetic macular edema: a pilot study. ( 29917217 )
2018
29
Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial. ( 29392288 )
2018
30
Evaluation of contrast sensitivity and other visual function outcomes in diabetic macular edema patients following treatment switch to aflibercept from ranibizumab. ( 29403260 )
2018
31
Comparison of the Effect of Intravitreal Dexamethasone Implant in Vitrectomized and Nonvitrectomized Eyes for the Treatment of Diabetic Macular Edema. ( 29850199 )
2018
32
Association Between Soluble CD14 in the Aqueous Humor and Hyperreflective Foci on Optical Coherence Tomography in Patients With Diabetic Macular Edema. ( 29392317 )
2018
33
Vision Outcomes Following Anti-Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical Practice. ( 29970221 )
2018
34
Evaluation of Vitrectomy with Planned Foveal Detachment as Surgical Treatment for Refractory Diabetic Macular Edema with or without Vitreomacular Interface Abnormality. ( 29854429 )
2018
35
A CCR2/5 Inhibitor, PF-04634817, Is Inferior to Monthly Ranibizumab in the Treatment of Diabetic Macular Edema. ( 29847672 )
2018
36
Short-Term Results of Intravitreal Triamcinolone Acetonide Combined with Cataract Surgery for Diabetic Macular Edema in Japan: In the Era of Anti-Vascular Endothelial Growth Factor Therapy. ( 29621780 )
2018
37
Vitreous and intraretinal macular changes in diabetic macular edema with and without tractional components. ( 30377798 )
2018
38
Hyperreflective foci on optical coherence tomography associate with treatment outcome for anti-VEGF in patients with diabetic macular edema. ( 30379920 )
2018
39
Adherence to Intravitreal Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Drugs in Diabetic Macular Edema in an Egyptian Population: A Health Belief Model. ( 30383436 )
2018
40
Evaluation of markers of outcome in real-world treatment of diabetic macular edema. ( 30386806 )
2018
41
Effect of Intravitreal Bevacizumab with or without Macular Photocoagulation for Diabetic Macular Edema: A Meta-Analysis. ( 30390227 )
2018
42
Short-term Efficacy of Micropulse Yellow Laser in Non-center-involving Diabetic Macular Edema: Preliminary Results. ( 30405946 )
2018
43
Glucose-regulated protein 78 in the aqueous humor in diabetic macular edema patients. ( 30407281 )
2018
44
Relationship between aqueous humor cytokine level changes and retinal vascular changes after intravitreal aflibercept for diabetic macular edema. ( 30410092 )
2018
45
The efficacy and safety of aflibercept and conbercept in diabetic macular edema. ( 30410308 )
2018
46
The efficacy and safety outcomes of the 0.19 mg fluocinolone acetonide implant after prior treatment with the 0.7 mg dexamethasone implant in patients with diabetic macular edema. ( 30410411 )
2018
47
OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY CHANGES AFTER SUBTHRESHOLD MICROPULSE YELLOW LASER IN DIABETIC MACULAR EDEMA. ( 30418391 )
2018
48
CASES IN REFINING MANAGEMENT OF DIABETIC MACULAR EDEMA. ( 30431537 )
2018
49
Fusing Results of Several Deep Learning Architectures for Automatic Classification of Normal and Diabetic Macular Edema in Optical Coherence Tomography. ( 30440485 )
2018
50
Automated Diabetic Macular Edema (DME) Analysis Using Fine Tuning with Inception-Resnet-v2 on OCT Images. ( 30440964 )
2018

Variations for Diabetic Macular Edema

Expression for Diabetic Macular Edema

Search GEO for disease gene expression data for Diabetic Macular Edema.

Pathways for Diabetic Macular Edema

Pathways related to Diabetic Macular Edema according to GeneCards Suite gene sharing:

(show all 41)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.88 CCL2 FGF2 ICAM1 IL6 NOS3 PRKCB
2
Show member pathways
13.39 CCL2 FGF2 ICAM1 IL6 TEK VEGFA
3
Show member pathways
13.25 CCL2 FGF2 IL6 NOS3 PRKCB TEK
4
Show member pathways
13.19 CCL2 FGF2 ICAM1 IL6 TEK VEGFA
5
Show member pathways
13.12 FGF2 IL6 NOS3 PRKCB TEK VEGFA
6
Show member pathways
12.87 CCL2 FGF2 ICAM1 IL6 PRKCB VEGFA
7
Show member pathways
12.84 FGF2 IL6 NOS3 TEK VEGFA
8 12.7 FGF2 IL6 PRKCB VEGFA
9
Show member pathways
12.66 CCL2 ICAM1 IL6 PRKCB
10
Show member pathways
12.63 FGF2 IL6 PRKCB VEGFA
11 12.62 FGF2 PRKCB TEK VEGFA
12
Show member pathways
12.59 FGF2 PRKCB TEK VEGFA
13
Show member pathways
12.48 CCL2 ICAM1 NOS3 PRKCB VEGFA
14
Show member pathways
12.36 CCL2 FGF2 IL6 NOS3 TEK
15
Show member pathways
12.15 CCL2 ICAM1 NOS3 PRKCB VEGFA
16
Show member pathways
12.09 FGF2 NOS3 PRKCB VEGFA
17 12.05 IL6 SST VEGFA
18 11.94 FGF2 IL6 VEGFA
19
Show member pathways
11.94 CCL2 FGF2 ICAM1 IL6
20 11.9 CCL2 ICAM1 NOS3 VEGFA
21 11.89 CCL2 ICAM1 IL6
22 11.83 CCL2 ICAM1 IL6
23
Show member pathways
11.82 IL6 NOS3 PRKCB
24 11.78 CCL2 FGF2 ICAM1 IL6 VEGFA
25 11.65 CCL2 FGF2 NOS3 TEK
26 11.65 IL6 NOS3 PRKCB TEK VEGFA
27 11.56 CCL2 FGF2 IL6
28
Show member pathways
11.55 ICAM1 IL6 VEGFA
29 11.51 CCL2 ICAM1 IL6 TEK VEGFA
30 11.43 CCL2 ICAM1 IL6
31 11.42 CCL2 ICAM1 IL6
32 11.4 FGF2 IL6 VEGFA
33 11.24 ICAM1 IL6 PRKCB
34 11.18 CCL2 IL6 NOS3
35 11.1 CCL2 ICAM1 IL6 NOS3 PRKCB VEGFA
36 11.09 FGF2 VEGFA
37 11.07 CCL2 ICAM1
38 10.93 CCL2 VEGFA
39 10.89 CCL2 FGF2 IL6 TEK
40 10.84 CCL2 ICAM1
41 10.64 FGF2 NOS3 TEK VEGFA

GO Terms for Diabetic Macular Edema

Cellular components related to Diabetic Macular Edema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.5 CCL2 FGF2 IL6 SERPINF1 SST TEK
2 extracellular space GO:0005615 9.17 CCL2 FGF2 ICAM1 IL6 SERPINF1 SST

Biological processes related to Diabetic Macular Edema according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.8 IL6 NOS3 VEGFA VSIR
2 response to hypoxia GO:0001666 9.74 ICAM1 TEK VEGFA
3 cellular response to lipopolysaccharide GO:0071222 9.73 CCL2 ICAM1 IL6
4 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.71 ICAM1 IL6 PRKCB
5 regulation of cell shape GO:0008360 9.7 CCL2 ICAM1 VEGFA
6 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.67 CCL2 FGF2 ICAM1 TEK
7 regulation of signaling receptor activity GO:0010469 9.65 CCL2 FGF2 IL6 SST VEGFA
8 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.61 ICAM1 IL6 VEGFA
9 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.6 FGF2 TEK
10 sprouting angiogenesis GO:0002040 9.59 TEK VEGFA
11 positive regulation of sprouting angiogenesis GO:1903672 9.58 FGF2 VEGFA
12 positive regulation of focal adhesion assembly GO:0051894 9.58 TEK VEGFA
13 positive regulation of endothelial cell proliferation GO:0001938 9.58 FGF2 TEK VEGFA
14 cell migration involved in sprouting angiogenesis GO:0002042 9.55 FGF2 VEGFA
15 cytokine-mediated signaling pathway GO:0019221 9.55 CCL2 FGF2 ICAM1 IL6 VEGFA
16 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.51 PRKCB VEGFA
17 positive regulation of blood vessel endothelial cell migration GO:0043536 9.5 FGF2 NOS3 VEGFA
18 negative regulation of calcium ion transport GO:0051926 9.48 ICAM1 NOS3
19 response to acidic pH GO:0010447 9.46 SERPINF1 SST
20 angiogenesis GO:0001525 9.35 CCL2 FGF2 NOS3 TEK VEGFA
21 positive regulation of angiogenesis GO:0045766 9.02 FGF2 NOS3 PRKCB TEK VEGFA

Molecular functions related to Diabetic Macular Edema according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.13 FGF2 IL6 VEGFA
2 cytokine activity GO:0005125 8.92 CCL2 FGF2 IL6 VEGFA

Sources for Diabetic Macular Edema

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....